These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2264021)

  • 21. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
    Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
    J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of sulfation on the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III.
    Schoen P; Wielders S; Petitou M; Lindhout T
    Thromb Res; 1990 Feb; 57(3):415-23. PubMed ID: 2315894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heparin binding domain of antithrombin III: characterization using a synthetic peptide directed polyclonal antibody.
    Smith JW; Dey N; Knauer DJ
    Biochemistry; 1990 Sep; 29(38):8950-7. PubMed ID: 2271570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
    Tazawa S; Ichikawa K; Misawa K; Fukuyama J; Hamano S; Miyata H; Sakuragawa N
    Thromb Res; 1995 Dec; 80(5):391-8. PubMed ID: 8588200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between human tissue thromboplastin and human antithrombin III.
    Hirahara K; Matsuishi T; Suzuki N; Kurata M
    Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):2984-7. PubMed ID: 2632043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparin surface immobilization through hydrophilic spacers: thrombin and antithrombin III binding kinetics.
    Byun Y; Jacobs HA; Kim SW
    J Biomater Sci Polym Ed; 1994; 6(1):1-13. PubMed ID: 7947469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
    Callas DD; Fareed J
    Thromb Res; 1995 Jun; 78(5):457-60. PubMed ID: 7544924
    [No Abstract]   [Full Text] [Related]  

  • 28. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of protamine sulfate with thrombin.
    Cobel-Geard RJ; Hassouna HI
    Am J Hematol; 1983 May; 14(3):227-33. PubMed ID: 6846326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of different heparins on the enhancement of the thrombin-antithrombin reaction.
    Oshima G
    Biol Chem Hoppe Seyler; 1990 Jan; 371(1):37-42. PubMed ID: 2322419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
    Asanuma K; Yoshikawa T; Yoshida K; Okamoto T; Asanuma Y; Hayashi T; Akita N; Oi T; Nishimura A; Hasegawa M; Sudo A
    Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):27-32. PubMed ID: 27262798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of heparin on the inhibition of the contact system enzymes.
    Colman RW; Scott CF; Pixley RA; de la Cadena RA
    Ann N Y Acad Sci; 1989; 556():95-103. PubMed ID: 2786690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A peptide model for the heparin binding site of antithrombin III.
    Lellouch AC; Lansbury PT
    Biochemistry; 1992 Mar; 31(8):2279-85. PubMed ID: 1540583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
    Granger CB; Becker R; Tracy RP; Califf RM; Topol EJ; Pieper KS; Ross AM; Roth S; Lambrew C; Bovill EG
    J Am Coll Cardiol; 1998 Mar; 31(3):497-505. PubMed ID: 9502626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
    Berry CN; Girardot C; Lecoffre C; Lunven C
    Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children.
    Mitchell L; Piovella F; Ofosu F; Andrew M
    Blood; 1991 Nov; 78(9):2299-304. PubMed ID: 1718494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits.
    Hara H; Tamao Y; Kikumoto R; Okamoto S
    Thromb Haemost; 1987 Apr; 57(2):165-70. PubMed ID: 3603410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of antithrombin III and thrombin to immobilized heparin under flow conditions.
    Byun Y; Jacobs HA; Kim SW
    Biotechnol Prog; 1996; 12(2):217-25. PubMed ID: 8857192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1.
    Rovelli G; Stone SR; Guidolin A; Sommer J; Monard D
    Biochemistry; 1992 Apr; 31(13):3542-9. PubMed ID: 1554734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithrombin III and heparin inactivation in thrombin involving reactions.
    Marciniak E
    Thromb Haemost; 1977 Aug; 38(2):486-93. PubMed ID: 579490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.